Moderna & Lonza announce worldwide collaboration to manufacture COVID-19 vaccine

Moderna who have never produced a product before, announced on May 1, 2020 that it had signed a 10-year strategic worldwide manufacturing collaboration with Lonza, with US manufacturing to start in July 2020. They plan to co-produce 1 billion doses annually, assuming a 50µg dose administered twice, 28 days apart. [1]

“Under the terms of the agreement, the companies plan to establish manufacturing suites at Lonza’s facilities in the United States and Switzerland for the manufacture of mRNA-1273 at both sites.”